Clinical Trials Browser

Neoplasms × Imatinib Mesylate × Clear all

NCT01046487 2026-03-13

PALANGI3

Phase 1 Completed

DermatologicGastrointestinalSarcoma

Uveal Melanoma, Chordoma, Carcinoma, Adenoid Cystic, Neoplasms, Desmoid Tumors, Dermatofibrosarcoma, Gastrointestinal Stromal Tumors

NCT05152472 2026-01-08

ATEZOGIST

Phase 2 Recruiting

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT05282108 2025-03-26

CARCML

MyeloidOther hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT05467189 2022-07-20

Antineoplastic Drugs in Elderly Patients

Neoplasms

NCT02461849 2022-06-15

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Phase 2 Unknown

Neoplasms

NCT03381053 2017-12-21

Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation

Neoplasms

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Phase 3 Terminated

307 enrolled 11 charts

LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00928642 2014-10-21

Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

Phase 2 Completed

8 enrolled 8 charts

Neoplasms, Ovarian Neoplasms

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Phase 1 Completed

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT00611689 2013-02-04

Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT00026169 2013-01-10

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

Phase 1 Completed

Neoplasms

NCT01083589 2012-01-11

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00250042 2011-09-20

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Neoplasms

NCT01271166 2011-01-06

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

Phase 1 Terminated

Neoplasms

NCT00180830 2006-09-11

Glivec Phase II Pediatric Study

Phase 2 Terminated

Neoplasms